Thermo Fisher Scientific $7.2 billion acquisition of Patheon

Overview:

• Thermo Fisher Scientific has acquired all of the issued and outstanding shares of Patheon for $35.00 per share in cash.
• The transaction represents a purchase price of approximately $7.2 billion, which includes the assumption of approximately $2.0 billion of net debt.
• DSM has an interest of 33% in the Pantheon from an year ago, when the stock price of a share was $21.
• Goldman Sachs & Co served as financial adviser to Thermo Fisher, while Morgan Stanley & Co acted as Patheon's adviser.

Katrin Kostadinova - Data analyst